Results 31 to 40 of about 1,591,431 (356)

Evaluation of the burden of HPV-related hospitalizations as a useful tool to increase awareness: 2007–2017 data from the sicilian hospital discharge records [PDF]

, 2020
In light of the implementation of human papillomavirus (HPV) prevention strategies, epidemiological studies in different geographical areas are required in order to assess the impact of HPV-related diseases.
Amato L., Amodio E., Candiloro S., Casuccio A., Costantino C., Maranto M., Marrella A., Palmeri S., Pizzo S., Restivo V., Vitale F.   +10 more
core   +1 more source

The Hajj 2019 Vaccine Requirements and Possible New Challenges [PDF]

, 2019
Each year millions of pilgrims perform the annual Hajj from more than 180 countries around the world. This is one of the largest mass gathering events and may result in the occurrence and spread of infectious diseases.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core   +1 more source

Evidence for antibody as a protective correlate for COVID-19 vaccines

medRxiv, 2021
Though eleven novel COVID-19 vaccines have demonstrated efficacy, additional affordable, scalable, and deliverable vaccines are needed to meet unprecedented global demand. With placebo-controlled efficacy trials becoming infeasible due to the roll out of
Kristen A. Earle, D. Ambrosino, A. Fiore-Gartland, D. Goldblatt, P. Gilbert, G. Siber, P. Dull, Stanley A Plotkin   +7 more
semanticscholar   +1 more source

Accounting Problems Under the Excess Profits Tax [PDF]

, 1943
DNA vaccines based on subunits from pathogens have several advantages over other vaccine strategies. DNA vaccines can easily be modified, they show good safety profiles, are stable and inexpensive to produce, and the immune response can be focused to the
A Biragyn, A Biragyn, A Biragyn, A Iwasaki, A Smed-Sorensen, A Viola, AB Fredriksen, AB Fredriksen, Agnete B. Fredriksen, AJ McMichael, AK Roos, B Ferraro, B Peng, Bjarne Bogen, BS Davis, C Cheong, C Coban, C Trumpfheller, D D’Ambrosio, DH Barouch, DP Snider, EB Compeer, EM Borroni, G Carayanniotis, G Grodeland, G Grodeland, G Nchinda, H Kawamura, H Qin, H Takahashi, HC Spang, I Oynebraten, Inger Øynebråten, J Aliberti, JD Altman, JJ Kim, Jorma Hinkula, K Ozato, KA Garver, KE Stephenson, KW Schjetne, L Cohn, L Norderhaug, L Qin, LJ Cruz, M Altfeld, M Charmoy, M Froyland, M Kreutz, M Mack, M Malissen, M Maurer, MA Liu, Mauricio M. Rodrigues, MS Neuberger, NY Sardesai, O Kew, OP Joffre, P Menten, PA Broliden, PA Ruffini, PF McKay, PJ Bergman, PJ Tacken, R Schiavo, R Song, RM Steinman, S Flingai, S Santra, T Schiffner, W Liu, WJ Karpus, WR Heath, Z Xiang   +73 more
core   +6 more sources

The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review

Human Vaccines & Immunotherapeutics, 2022
With the relatively rapid development of the COVID-19 pandemic, vaccine development has become crucial for limiting disease transmission. The accelerated growth in the approved COVID-19 vaccines has sparked concerns about their efficacies which have been
Ibrahim Mohammed, Areej Nauman, Pradipta Paul, Sanjith Ganesan, Kuan-Han Chen, S. Jalil, Shahd Jaouni, Hussam Kawas, Wafa Khan, Ahamed Lazim Vattoth, Y. Al-Hashimi, Ahmed Fares, Rached Zeghlache, Dalia Zakaria   +13 more
semanticscholar   +1 more source

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

The Lancet Oncology, 2022
Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic.
C. Lorentzen, J. Haanen, Ö. Met, I. Svane   +3 more
semanticscholar   +1 more source

Acknowledgement to Reviewers of Vaccines in 2018

Vaccines, 2019
Rigorous peer-review is the corner-stone of high-quality academic publishing. [...]
Vaccines Editorial Office
doaj   +1 more source

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

Nature Reviews Clinical Oncology, 2021
Within the past decade, the field of immunotherapy has revolutionized the treatment of many cancers with the development and regulatory approval of various immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies in diverse indications.
Eryn Blass, P. Ott
semanticscholar   +1 more source

Acknowledgement to Reviewers of Vaccines in 2015

Vaccines, 2016
The editors of Vaccines would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2015. [...]
Vaccines Editorial Office
doaj   +1 more source

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2

npj Vaccines, 2023
Since the original outbreak of the SARS-CoV-2 virus, several rapidly spreading SARS-CoV-2 variants of concern (VOC) have emerged. Here, we show that a single dose of Ad26.COV2.S (based on the Wuhan-Hu-1 spike variant) protects against the Gamma and Delta
Maarten Swart, Joan van der Lubbe, Sonja Schmit-Tillemans, Ella van Huizen, Johan Verspuij, Ana Izquierdo Gil, Ying Choi, Chenandly Daal, Aditya Perkasa, Adriaan de Wilde, Erwin Claassen, Rineke de Jong, Katrin E. Wiese, Lisette Cornelissen, Marieke van Es, Marjolein van Heerden, Eleni Kourkouta, Issam Tahiri, Michel Mulders, Jessica Vreugdenhil, Karin Feddes - de Boer, Leacky Muchene, Jeroen Tolboom, Liesbeth Dekking, Jarek Juraszek, Jort Vellinga, Jerome Custers, Rinke Bos, Hanneke Schuitemaker, Frank Wegmann, Ramon Roozendaal, Harmjan Kuipers, Roland Zahn   +32 more
doaj   +1 more source